TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01517815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem or Piperacillin/Tazobactam
Description: This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem or Piperacillin/Tazobactam
Description: This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value.
Study: NCT02468388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol
Description: maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: xylitol
Description: xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gum base
Description: gum base: 99% gum base; two pellets for 10 min five times each day
Study: NCT02987803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data
Description: The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
Study: NCT03686020

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme Linked Immunosorbent assay (ELISA)
Description: measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme Linked Immunosorbent assay (ELISA)
Description: measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme Linked Immunosorbent assay (ELISA)
Description: measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)
Study: NCT03323723

Intervention type: DEVICE
Group type: OTHER
Intervention: SUI Device
Description: Pessary SUI device
Study: NCT01369602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: single dose 300-mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: single dose 300-mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: single dose 300-mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: single dose 300-mg
Study: NCT04438590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kelulut Honey
Description: The Substance being tested to be used as an alternative

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carborie
Description: The commercially available substance
Study: NCT00655850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: * Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~* Dexamethasone 20mg, intravenously (IV)~* Diphenhydramine 50 mg IV~* Ranitidine 50 mg IV~* Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~* The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~* Dose Level 1 ________80 mg/m2/weekly~* Dose Level -1 ________70 mg/m2/weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Premedication~* Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~* Prior to receiving paclitaxel chemotherapy~* Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~* The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~* Dose Level 2 ________300 mg/m2/weekly~* Dose Level 1 ________200 mg/m2/weekly~* Dose Level -1 ________150 mg/m2/weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avastin
Description: * The dose of Avastin is 10 mg/kg IV every 2 weeks~* It will be administered following the administration of chemotherapy~* The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~* It should not be administered or mixed with dextrose solutions.
Study: NCT02813421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM Informed
Study: NCT02760264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.25 mg/kg/day
Description: Oral administration of 0.25 mg/kg/day daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.75 mg/kg/day
Description: Oral administration of 0.75 mg/kg/day daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 2.0 mg/kg/day
Description: Oral administration of 2.0 mg/kg/day daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 6.0 mg/kg/day
Description: Oral administration of 6 mg/kg/day daily for 14 days.
Study: NCT00911807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin + donepezil
Description: Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin + placebo
Description: Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil + placebo
Description: Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.
Study: NCT01088282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Implantation of multifocal or monofocal IOL

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Cataract surgery
Description: Implantation of multifocal or monofocal IOL
Study: NCT03490474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Inducing Massage
Description: Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Massage
Description: Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coldpressor
Description: Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
Study: NCT03589248

Intervention type: DIAGNOSTIC_TEST
Intervention: GIF score
Description: assessment by GIF score

Intervention type: DIAGNOSTIC_TEST
Intervention: GIF score
Description: assessment by GIF score

Intervention type: DIAGNOSTIC_TEST
Intervention: US score
Description: assessment by ultrasonography score

Intervention type: DIAGNOSTIC_TEST
Intervention: US score
Description: assessment by ultrasonography score
Study: NCT01829113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
Study: NCT01246960

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously
Study: NCT05077371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support program
Description: The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support program
Description: The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.
Study: NCT01246960

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: Administered intravenously
Study: NCT05239559

Intervention type: DEVICE
Intervention: Bubble CPAP oxygen delivery device
Description: In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~1. Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~2. A nasal interface connecting the child's airway with the circuit:~3. An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines.
Study: NCT03156595

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nurse interview
Description: Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
Study: NCT00313950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella
Description: 0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
Study: NCT03156595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis sessions
Description: Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
Study: NCT04491032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal anesthesia
Description: Caudal epidural injection will be performed after induction of general anesthesia.
Study: NCT00313950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
Description: 0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella
Description: 0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
Study: NCT00846261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use it to treatment bone nonunion (Ilzarov)
Description: Detect the variation of limb lengthening
Study: NCT01317615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
Study: NCT01211964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 22811
Description: Oral administration of solution and tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 22811
Description: Oral administration of solution and tablet.
Study: NCT01234610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
Study: NCT03430414

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptome Analysis
Description: Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptome Analysis
Description: Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies
Study: NCT02515838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevuparin
Description: The Drug Product sevuparin solution for IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for IV infusion
Study: NCT01211964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 22811
Description: Oral administration of solution and tablet.
Study: NCT02206763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Description: Tablet(s) administered orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tablet(s) administered orally once daily.
Study: NCT02213913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT03865758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN2L computer system
Description: Therapists will use the IN2L computer system to choose videos, music, games and exercise specific to the rehabilitation needs and personal preferences of patients.
Study: NCT03503084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical Yang's TCC exercise
Study: NCT03706261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK-6240
Description: Administration of 5 mCi of 18F-MK-6240 for tau PET.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben
Description: Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.
Study: NCT03233919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comprehensive remote ischaemic conditioning
Description: comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI.
Study: NCT04050098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release
Description: Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin tartrate sesquihydrate and metformin
Description: Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
Study: NCT01487096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: film-coated tablet~oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: film-coated tablet~oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (placebo for teriflunomide)
Description: film-coated tablet~oral administration
Study: NCT03775772

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oral Health
Description: * test group will receive an dental hygiene program for one year~* control group will remain with dental hygiene regime like done before study participation (maximum of two dental hygiene Treatments per year)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bite Force
Description: * test group will receive physiotherapy with the aim of increasing muscle strength in chewing muscles for 3 months~* control group will remain without such training
Study: NCT00005096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT01693055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltheraTM 100 shots
Description: UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
Study: NCT00349752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: certolizumab pegol 400 mg
Description: Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
Study: NCT05041322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take placebo pills (twice a day) for 14 Days.
Study: NCT01434381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel